Abstract 1673P
Background
Imposter Syndrome (IS) is defined as “the inability to internalize achievement and a tendency to attribute success to external factors such as luck, error, or personal connections. It has been associated with psychological distress, emotional suffering, and significant mental health issues. It has also been associated with Burnout (BO), characterized by the emotional exhaustion of individuals in their careers, depersonalization toward other individuals, and a decrease in the sense of personal accomplishments. The study aimed to evaluate the factors associated with IS and its association with BO in medical oncologists (MOs).
Methods
A cross-sectional study was conducted focusing on the MOs actively working in the field. They were invited to the study via mailing list. The sociodemographic and academic data were collected. The IS scores (ISS) was tested using the Clance imposter phenomenon Scale and BO was tested by using the Maslach burnout inventory. The subscales of BO; emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA) were analyzed. The characteristics associated with IS and BO were tested by univariate and multivariate analysis.
Results
In the study, 417 MOs with a median age of 40(29-68) were evaluated. The mean of ISS was 50.8+/-15.3, and 122(29.3%) participants had high ISS. The multivariate analysis revealed that female gender was the only factor associated with high ISS (OR: 1.85, CI95%, 1.1- 2.9, p=0.009). While there was a strong positive correlation between ISS and EE (r=0.54, p<0.001) and DP (r=0.48, p<0.001), a strong and negative correlation was found between ISS and PA score (r= -0.41, p<0.001). In the multivariate analysis; high ISS score was the only statistically significant parameter associated with a high EE score (OR:5.03, CI 95% 3.1-8.0, p<0.001), high DP scores (OR=3.4, CI 95% 1.8- 6.5, p<0.001) and low PA scores. (OR=3.73, CI 95% 1.9- 7.1, p<0.001).
Conclusions
The results of the study indicated that IS is prevalent in MOs. The MOs with IS were more emotionally exhausted and more depersonalized. In addition, they had less feeling of personal accomplishment. The IS and its consequences on MOs should be further studied and the strategies to cope with IS should be developed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11